Literature DB >> 11687922

Insulin sensitivity with respect to glucose metabolism in hypertension-prone men did not predict the blood pressure increase in 5 years.

I Mattiasson1, T Endre, U L Hulthén.   

Abstract

OBJECTIVES: To evaluate peripheral insulin stimulated glucose uptake as a predictor for increase in blood pressure in hypertension-prone men.
DESIGN: A follow-up study 5 years after a primary investigation that included an euglycaemic hyperinsulinaemic clamp to evaluate insulin sensitivity.
SUBJECTS: Thirty-two men with a family history of hypertension (relatives) and 22 men with no hypertension in the family (controls). All were normotensive and had a normal glucose tolerance. MAIN OUTCOME MEASURES: Change in blood pressure over 5 years and its relation to the values obtained in the basal investigation.
RESULTS: Systolic and diastolic blood pressure increased in both groups during the 5 years, but diastolic blood pressure increased more in relatives than in controls (11 mm Hg vs 5 mm Hg, P = 0.03). The change in diastolic blood pressure was correlated to basal BMI (r = 0.43, P = 0.02) only in controls. There were no correlations between the change in blood pressure during the 5 years and basal glucose disposal nor to any of the other basal parameters in either relatives or controls.
CONCLUSIONS: Insulin sensitivity did not predict the change in blood pressure during the 5 years either in hypertension-prone men or in controls, nor did anthropometrical measurements, basal and stimulated insulin and maximal oxygen uptake. The blood pressure increase was related to basal BMI only in controls.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11687922     DOI: 10.1038/sj.jhh.1001272

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  1 in total

1.  Insulin resistance and risk of incident hypertension among men.

Authors:  Tai-Shuan Lai; Gary C Curhan; John P Forman
Journal:  J Clin Hypertens (Greenwich)       Date:  2009-09       Impact factor: 3.738

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.